No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
KROS241220C30000
- 0.03
- -0.02-40.00%
15min DelayClose Dec 20 16:00 ET
0.03High0.03Low
0.03Open0.05Pre Close1 Volume299 Open Interest30.00Strike Price3.00Turnover9663.46%IV76.34%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0201Delta0.0110Gamma567.67Leverage Ratio-37.1655Theta0.0000Rho11.42Eff Leverage0.0000Vega
Intraday
- 5D
- Daily
News
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63
Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63
Keros Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Keros Therapeutics (KROS)
Piper Sandler Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $40
Keros Therapeutics Cut to Neutral From Buy by Guggenheim